Flu redux and RIT: friendly fire in the treatment of low-grade lymphoma ----------------------------------------------------------------------------------------------------------------Leo I. Gordon NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE
Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I 131 tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.
T he problem that Boice 1 has called "friendly fire," or the development of secondary malignancies after treatment, has been studied extensively over the past 25 years. As patients live longer, we will be faced with more questions about late effects. In low-grade lymphoma (LGL), the demonstration of the CD20 target and the subsequent development of monoclonal antibodies (rituximab) as therapeutic ligands has improved response rates and allowed more therapeutic options. Based on the observation that external beam radiation is an effective modality that is limited by the confines of the beam, investigators have developed novel radioimmunoconjugates that use low-energy I 131 tositumomab 2 or higherenergy Y 90 ibritumomab tiuxetan (Zevalin) 3 attached to a murine anti-CD20 antibody.
Data have suggested that response rates are high and durable and that there is no crossresistance with either rituximab or prior chemotherapy. The fear, however, was that the radiation would lead to a higher incidence of second malignancies. This concern was not unreasonable, as the radionuclide P 32 was associated with a higher-than-expected incidence of leukemia in patients with polycythemia vera, 4 but large studies with I 131 in thyroid disease have found no increase in treatmentrelated acute myeloid leukemia (tAML) or treatment-related myelodysplastic syndrome (tMDS). 5 In this issue of Blood, Bennett and colleagues observed that the risk of tAML or tMDS was not higher than would be expected (about 1.1% per year in confirmed cases) from alkylating agents alone when radioimmunotherapy (RIT) was used after alkylating agent exposure in 995 heavily treated patients and was 0% in 76 previously untreated patients. This should allow further careful trials of RIT used earlier in the course of the disease. The observation that the incidence of tAML or tMDS was highest in patients with thrombocytopenia and in those who had been previously exposed to the purine analogue fludarabine deserves attention. In earlier studies with Zevalin, prior exposure to fludarabine was associated with prolonged thrombocytopenia.
In this issue of Blood, McLaughlin and colleagues report on 202 patients with LGL who were treated with either fludarabine, mitoxantrone, and dexamethasone (FND) with or without rituximab, followed by interferon alpha (IFN␣), or with alternating triple therapy (ATT) with or without rituximab, followed by IFN␣ (ATT has no fludarabine). With a median follow-up of 42 months, 8 patients (4%) developed tMDS or tAML. Of these, 6 received FND with or without rituximab and IFN␣, but 2 also received alkylating agents. Two received ATT with or without rituximab and IFN␣. The cytogenetic profile of these cases included frequent chromosome 5 (5q-) and 7 (monosomy 7) abnormalities, a pattern that has been described before, especially after alkylating agent exposure. No patient had an 11q23 abnormality. These observations, combined with the finding by Bennett et al that prior fludarabine exposure was associated with a higher risk of tMDS or tAML in patients receiving RIT and with a report suggesting that in chronic lymphocytic leukemia combinations of alkylating agents and fludara- 6 should give investigators and clinicians pause. We must rethink our combination regimens (alkylating agents and purine analogues) and consider testing RIT before fludarabine in future clinical trials in LGL.
Pedersen-Bjergaard et al 7 have provided direction by describing a genetic pathway that characterizes therapy-related tMDS or tAML. In this model (see figure) , 8 pathways based on specific cytogenetic abnormalities are described, and within these pathways, 3 etiologies emerge: (1) exposure to alkylating agents, (2) exposure to topoisomerase II inhibitors, and (3) spontaneous endogenous recombinations unrelated to chemotherapy. As we improve our therapeutic armamentarium by using purine analogues and RIT and offer either sequential or combined therapy to patients, we may find new patterns and increased risk. ---------------------------------------------------------------------------------------------------------------- 
Toward individualized dosing in pediatric ALL
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In this issue of Blood, Rocha and colleagues provide evidence for the independent prognostic significance of pharmacogenomic parameters on clinical outcome in childhood acute lymphoblastic leukemia. C urrent treatment for pediatric acute lymphoblastic leukemia (ALL) results in cure in approximately 80% of patients, but some children still suffer from treatment failure or treatment-related mortality. Apart from leukemia cell drug resistance, 1 it is increasingly recognized that treatment may fail due to suboptimal dosing related to inherited variations in drug-metabolizing genes, addressed in the field of pharmacogenomics. This field may concern enzymes that result in either activation or detoxification of drugs. The available data sometimes provide conflicting results regarding the influence of pharmacogenetics on outcome, a problem that may be related to the retrospective nature of most studies. 2 In this issue of Blood, Rocha and colleagues describe a prospective study in which 16 genetic polymorphisms were screened in children treated according to a single protocol, although patients were stratified in high-risk and low-risk arms. It appeared that the glutathione S-transferase (GST) GSTM1 non-null genotype was significantly associated with an increased relapse rate in high-risk patients and was further increased by the thymidylate synthetase (TYMS) 3/3 genotype. Both genotypes did indeed result in higher expression levels of the enzymes for which they encode.
In multivariate analysis these 2 genotypes showed independent prognostic significance-together with the presence of MLL-AF4 and minimal residual disease (MRD) levels. No genotype was identified associated with relapse in the low-risk group. The authors also addressed pharmacogenetic risk factors for central nervous system (CNS) relapse, and showed that 2 polymorphisms in the vitamin D receptor were associated with CNS relapse in high-risk patients. This relationship is probably indirect, as the vitamin D receptor is linked to the expression of CYP3A4 and possibly also p-glycoprotein. In low-risk patients the TYMS 3/3 genotype predisposed for CNS relapse.
This study clearly demonstrates the proof of principle that suboptimal dosing based on genetic variation in the host plays a role in treatment outcome in pediatric ALL. However, a number of unresolved issues remain. First, researchers must determine whether the influence of genotypes on treatment outcome is protocol specific, as suggested by the lack of prognostic significance of GST genotypes in another large prospective study. 3 No relevant pharmacogenomic risk factors were identified in low-risk patients, raising the question of whether pharmacogenomics is more relevant in the context of intensive chemotherapy or whether the relevant genes are in fact unknown, 1 which may also explain why many of the polymorphisms did not correlate with outcome. For some of the genotypes, the absence of correlation is rather surprising; the thiopurine methyltransferase genotype, which was recently shown to be related to MRD levels in another prospective study, is one such example. 4 Furthermore, no relationships were found with treatment-related mortality.
Despite these limitations, the data do provide an opportunity to further improve outcome in pediatric ALL. From a practical point of view this may be easier to achieve for the TYMS 3/3 genotype than for non-null GSTM1 patients, as the latter genotype is involved in detoxification of many different antileukemic agents. The St. Jude's group has already shown that individualized dosing of methotrexate improves outcome in pediatric ALL. 5 ■
